TerminatedPhase 2

Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation

Stopped: Due to inability to meet accrual goals within the funding period

United States362 participantsStarted 2011-09

Plain-language summary

All people who have a heart transplant are at risk for developing cardiac allograft vasculopathy (CAV). CAV means narrowing of the heart transplant vessels, which is associated with poor heart transplant function. People who develop antibodies after transplant have a higher risk of developing CAV. Infections, high cholesterol, and rejection also increase the risk of developing CAV. People who develop CAV usually have to receive another transplant.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓-Negative PRA within 12 weeks prior to transplant (Local HLA Center Testing) using one of the following:

What they're measuring

Change in Percent Atheroma Volume (PAV)

Timeframe: Baseline, 1 year

Trial details

NCT IDNCT01278745

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)

Sponsor typeNIH

Study typeINTERVENTIONAL

Primary completion2015-10

Results submitted2016-12-01

View on ClinicalTrials.gov More Cardiac Allograft Vasculopathy trials